Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Jinan, China.
Pathol Oncol Res. 2022 Feb 23;28:1610012. doi: 10.3389/pore.2022.1610012. eCollection 2022.
The purpose of our current study was to establish a long non-coding RNA(lncRNA) signature and assess its prognostic and diagnostic power in papillary thyroid cancer (PTC). LncRNA expression profiles were obtained from the Cancer Genome Atlas (TCGA). The key module and hub lncRNAs related to PTC were determined by weighted gene co-expression network analysis (WGCNA) and LASSO Cox regression analyses, respectively. Functional enrichment analyses, including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene set enrichment analysis were implemented to analyze the possible biological processes and signaling pathways of hub lncRNAs. Associations between key lncRNA expressions and tumor-infiltrating immune cells were identified using the TIMER website, and proportions of immune cells in high/low risk score groups were compared. Kaplan-Meier Plotter was used to evaluate the prognostic significance of hub genes in PTC. A diagnostic model was conducted with logistic regression analysis, and its diagnostic performance was assessed by calibration/receiver operating characteristic curves and principal component analysis. A nine-lncRNAs signature (SLC12A5-AS1, LINC02028, KIZ-AS1, LINC02019, LINC01877, LINC01444, LINC01176, LINC01290, and LINC00581) was established in PTC, which has significant diagnostic and prognostic power. Functional enrichment analyses elucidated the regulatory mechanism of the nine-lncRNAs signature in the development of PTC. This signature and expressions of nine hub lncRNAs were correlated with the distributions of tumor infiltrating immune cells. A diagnostic nomogram was also established for PTC. By comparing with the published models with less than or equal to nine lncRNAs, our signature showed a preferable performace for prognosis prediction. In conclusion, our present research established an innovative nine-lncRNAs signature and a six-lncRNAs nomogram that might act as a potential indicator for PTC prognosis and diagnosis, which could be conducive to the PTC treatment.
本研究旨在建立长链非编码 RNA(lncRNA)特征,并评估其在甲状腺乳头状癌(PTC)中的预后和诊断价值。lncRNA 表达谱从癌症基因组图谱(TCGA)获得。通过加权基因共表达网络分析(WGCNA)和 LASSO Cox 回归分析分别确定与 PTC 相关的关键模块和枢纽 lncRNAs。进行了功能富集分析,包括基因本体论和京都基因与基因组百科全书(KEGG)以及基因集富集分析,以分析枢纽 lncRNAs 的可能生物学过程和信号通路。使用 TIMER 网站确定关键 lncRNA 表达与肿瘤浸润免疫细胞之间的关联,并比较高/低风险评分组中免疫细胞的比例。Kaplan-Meier Plotter 用于评估 PTC 中枢纽基因的预后意义。使用逻辑回归分析构建诊断模型,并通过校准/接受者操作特征曲线和主成分分析评估其诊断性能。在 PTC 中建立了一个由九个 lncRNAs 组成的特征(SLC12A5-AS1、LINC02028、KIZ-AS1、LINC02019、LINC01877、LINC01444、LINC01176、LINC01290 和 LINC00581),具有显著的诊断和预后价值。功能富集分析阐明了九个 lncRNAs 特征在 PTC 发展中的调控机制。该特征和九个枢纽 lncRNAs 的表达与肿瘤浸润免疫细胞的分布相关。还建立了用于 PTC 的诊断列线图。与发表的少于或等于九个 lncRNAs 的模型相比,我们的特征在预后预测方面表现更好。总之,本研究建立了一个创新性的九个 lncRNAs 特征和一个六个 lncRNAs 列线图,可作为 PTC 预后和诊断的潜在指标,有助于 PTC 的治疗。